Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 24 FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
FDA-approved: Prevention of pregnancy.,Off-label: Treatment of acne vulgaris, regulation of menstrual disorders, dysmenorrhea.
Prevention of pregnancy (FDA-approved)
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation and glucuronidation; norethindrone is metabolized via reduction, glucuronidation, and sulfation, primarily by CYP3A4 and CYP2E1.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~97% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. Ethinyl estradiol: ~97% bound, primarily to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: approximately 3.6 L/kg; Ethinyl estradiol: approximately 2.7 L/kg. Large Vd indicates extensive tissue distribution (reproductive organs, liver, fat).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: approximately 64% (oral) due to first-pass metabolism. Ethinyl estradiol: approximately 55% (oral) due to first-pass metabolism and intestinal conjugation.
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Not recommended for use in patients with severe renal impairment or end-stage renal disease due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic disease, including acute hepatitis, hepatic adenomas, or cirrhosis. No dose adjustment recommendations; avoid use.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Approved for use in postmenarchal females. Dosage same as adults: one active tablet daily for 24 days followed by iron-containing tablets for 4 days. Not indicated for premenarchal females.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dosing recommendations; therapy should be discontinued if menopause occurs.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from combination oral contraceptives, especially in women over 35 who smoke >15 cigarettes/day.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders, hypertension, gallbladder disease, hepatic neoplasia, retinal thrombosis, carbohydrate/lipid effects, headache, menstrual irregularities, depression, hereditary angioedema.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis/thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, hepatic tumors (benign/malignant), hypersensitivity to any component, smoking >15 cigarettes/day in women >35 years.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. Alcohol does not affect efficacy but may worsen side effects like nausea or dizziness. The ferrous fumarate in placebo pills may be absorbed better with vitamin C (e.g., orange juice).
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adverse effects on fetal development including possible estrogenic effects on fetal genitalia. Discontinue if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio not established. Use may reduce milk production and composition. Not recommended during breastfeeding; consider alternative contraception.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments are applicable as Loestrin 24 Fe is contraindicated during pregnancy. Discontinue immediately upon pregnancy confirmation.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Loestrin 24 Fe contains norethindrone acetate and ethinyl estradiol with 24 active tablets and 4 ferrous fumarate placebo tablets. It is approved for contraception and acne vulgaris in women ≥16 years. The shortened hormone-free interval (4 vs 7 days) may reduce breakthrough bleeding and improve ovarian suppression. Counsel patients that the iron tablets are not active hormone and serve only to maintain routine. If a dose is missed, the patient should take the missed pill as soon as remembered and continue the remaining pills, possibly requiring backup contraception. Breakthrough bleeding is common in the first few cycles; rule out pregnancy if persistent.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, preferably after a meal to reduce nausea.,The 4 brown pills contain iron; they are not hormonal and are taken during the placebo week.,Use backup contraception (condoms) for the first 7 days if starting for the first time or after a break.,Missing pills increases risk of pregnancy; follow package instructions for missed doses.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Report severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.,Regular gynecological exams and blood pressure monitoring are recommended.,Store at room temperature away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 24 FE vs AFIRMELLE, answered by our medical review team.
LOESTRIN 24 FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 24 FE and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 24 FE is: One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 24 FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 24 FE is classified as Category C. First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adv. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.